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326Objective: Our objective was to analyze the results of transapical aortic valve implantation in high-risk patients
with aortic stenosis at up to 3 years after the procedure.
Methods:A total of 299 patients underwent transapical aortic valve implantation from February 2006 until Jan-
uary 2010 using the Edwards SAPIEN transcatheter xenograft. Mean patient age was 82  6 years and 70%
were female. Logistic EuroSCORE and Society of Thoracic Surgeons score predicted risks for mortality
were 31%  16% and 12%  8%, respectively. All patients were treated in a hybrid operative theater by
a team of anesthetists, cardiologists and cardiac surgeons.
Results: Successful valve implantation was performed in all patients. Transapical aortic valve implantation was
uneventful in 267 patients (89.3%), whereas 32 patients (10.7%) required additional interventions. Such
interventions included cardiopulmonary bypass support in 18, implantation of a second SAPIEN valve in 15,
coronary intervention in 9, conversion to conventional surgery in 6, and annulus perforation in 3 patients (not
mutually exclusive). Intraprocedural stroke was not observed in any patient, although 2 (0.7%) patients had
a delayed stroke during their hospital stay. Overall survival was 91% at 30 days, 73% at 1 year, 68% at 2 years,
and 58% at 3 years.
Conclusions: Transapical aortic valve implantation can be performed with good outcomes in high-risk patients
with aortic stenosis. Perioperative complications occur in approximately 10% of patients, and a variety of
interventions are required for these events. We believe a team approach is therefore essential for the success
of transapical aortic valve implantation (J Thorac Cardiovasc Surg 2012;143:326-31)Conventional aortic valve replacement (AVR) is a standard-
ized procedure with very good outcomes in patients with
aortic stenosis (AS).1-3 Over time, however, patients requir-
ing AVR have been increasing in age with an increasing
number of comorbidities. Parallel to this trend, transcath-
eter (T) aortic valve implantation (AVI) techniques have
been developed for minimally invasive therapy. T-AVI is
currently being recommended for elderly high-risk patients
only.4 After CE approval in 2008, these procedures are gain-
ing increasing acceptance in Europe. For example, transap-
ical (TA) AVI is being performed in more than 50% of all
German cardiac surgical centers.
For T-AVI a retrograde transfemoral (TF) or an antegrade
TA approach is available.5-11 The CoreValve prosthesis
(Medtronic, Inc, Minneapolis, Minn) is being used for TF
implantations and the SAPIEN prosthesis (Edwards Life-
sciences, Inc, Irvine, Calif) for TF and TA implantations.
There is no randomized clinical trial comparing clinicale Departments of Cardiac Surgery,a Cardiology,b and Anaesthesia,c Univer-
eipzig, Heart Center, Leipzig, Germany.
res: Authors have nothing to disclose with regard to commercial support.
d for publication May 24, 2010; revisions received Oct 5, 2010; accepted for
ation Oct 20, 2010; available ahead of print July 4, 2011.
for reprints: ThomasWalther, MD, PhD, Kerckhoff Klinik Heart Center, De-
ent Cardiac Surgery, Benekestrasse 2-8, D–61231 Bad Nauheim, Germany
il: t.walther@kerckhoff-klinik.de).
23/$36.00
ht  2012 by The American Association for Thoracic Surgery
016/j.jtcvs.2010.10.063
The Journal of Thoracic and Cardiovascular Surgresults using the TF and the TA approaches at present;
thus the superiority or inferiority of these approaches has
not yet been proven. In addition, large-volume single-center
results as well as intermediate-term outcome of TA-AVI
have not yet been reported. The aim of our study was there-
fore to analyze the outcomes of TA-AVI in a large number
of consecutive patients, as well as to characterize the
follow-up status at up to 3 years after the procedure.
METHODS
From February 2006 until January 2010, a total of 299 patients under-
went TA-AVI using the Edwards SAPIEN transcatheter xenograft. All pa-
tients gave written informed consent and the study was approved by the
institutional ethics review board. Elderly patients with severe AS and
a high risk profile (additive EuroSCORE  9) or known risk factors for
conventional surgery such as a porcelain aorta, chest radiation, previous
cardiac surgery, or previous mediastinitis underwent the screening protocol
for T-AVI. Such screening started with transesophageal echocardiography
to measure the aortic annulus diameter and determine the pattern of leaflet
calcification, as well as to exclude any other significant valve dysfunction.
A minimum device oversizing of 1 mm in exceptional cases (ie, patients at
very high risk for conventional surgery with a ‘‘borderline’’ annulus diam-
eter) and 2 mm in all other patients was required. Cardiac catheterization
was performed to exclude coronary artery disease. Patients with suspicion
of a short aortic annulus to coronary artery distance on cardiac catheteriza-
tion underwent additional computed tomographic visualization of the aor-
tic root to more accurately determine this distance. In addition, pulmonary
function testing and carotid duplex studies were performed routinely in all
patients. All patients who were referred to our department with symptom-
atic AS that fulfilled the abovementioned risk criteria were screened for po-
tential TA-AVI. Patients were discussed by the transcatheter valve team,
consisting of cardiologists and cardiac surgeons, before the implantationery c February 2012
TABLE 1. Preoperative patient characteristics
N 299
Age (y) 82.1  6.4
Female (n/%) 209 (70%)
Ejection fraction 55  14
Prior CVA/TIA 56 (18.7%)
Pulmonary hypertension 80 (26.8%)
Previous cardiac surgery 84 (28.1%)
Peripheral vascular disease 141 (47.2%)
Porcelain aorta 39 (13%)
Chronic pulmonary disease 129 (43.1%)
FEV1<50% of normal 18 (6%)
FEV1 50%-70% of normal 50 (16.7%)
VC<50% of normal 25 (8.4%)
VC 50%-70% of normal 63 (21.1%)
Creatinine>200 mmol/L 26 (8.7%)
Chronic dialysis 8 (2.7%)
CVA, Cerebrocascular accident; TIA, transitory ischemic attack; FEV1, functional ex-
piratory capacity in 1 second; VC, vital capacity.
Abbreviations and Acronyms
AVI ¼ aortic valve implantation
AS ¼ aortic stenosis
AVR ¼ aortic valve replacement
CPB ¼ cardiopulmonary bypass
FEV1 ¼ functional expiratory volume in 1 second
STS ¼ Society of Thoracic Surgeons
T-AVI ¼ transcatheter aortic valve implantation
TA ¼ transapical
TF ¼ transfemoral
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ology department were investigated with a ‘‘TF first’’ intention whereas
those who were referred directly to our cardiac surgery department were
investigated with a ‘‘TA first’’ approach. Patient-specific factors were
also considered when deciding on the procedural approach. For example,
patients with severe peripheral vascular disease or small femoral arteries
(<7 mm in diameter) were preferentially treated with TA-AVI and patients
with severe respiratory dysfunction (functional expiratory volume in 1 sec-
ond [FEV1]<50% of predicted) were preferentially treated with TF-AVI.
TA-AVI was performed in a hybrid operative theater by a team of cardiac
anesthetists, cardiologists, and cardiac surgeons in a standard fashion as
described previously.12 Heparin (100 IU/kg) was administered during the
procedure to achieve an activated clotting time of 300 seconds. Transtho-
racic echocardiography was performed before discharge in all patients
and at yearly intervals thereafter in the majority of patients. Follow-up con-
sisted of mail and/or telephone interview of patients and/or their family
members and was supplemented by information from the patients’ cardiol-
ogists and/or family physicians. Postoperative medication consisted of as-
pirin (100 mg/d) only in patients who were in sinus rhythm and of
additional clopidogrel or warfarin treatment if required for other indica-
tions, for example, stent placement or chronic atrial fibrillation.
During the study period of 4 years, a total of 1700 patients underwent
isolated conventional AVR at our center. The annual number of isolated
AVR procedures increased slightly over the study period, in parallel with
the increasing number of T-AVI procedures. Approximately 700 high-
risk patients were entered into the screening process for T-AVI, and approx-
imately half of those patients were treated with TF-AVI and the other half
with TA-AVI.TABLE 2. Perioperative parameters and outcomes
N 299
Logistic EuroSCORE 31%  15.8%
STS score 12%  7.7%
Thirty-day mortality 8.7%
Annulus diameter 22.7  1.5 mm
SAPIEN valve diameter 25.2  1.5 mm
Surgical bleeding
Chest wall 1% (n ¼ 3)
Left ventricular apex 1% (n ¼ 3)
Conversion to sternotomy and conventional AVR 2% (n ¼ 6)
Contrast dye 99  64 mL
Endocarditis 0.4% (n ¼ 1)STATISTICAL ANALYSIS
Continuous variables are expressed as mean  standard
deviation for those variables with a gaussian distribution or
as median values only for nonnormally distributed data. Cat-
egorical data are expressed as proportions. Independent con-
tinuous variables were compared by the 2-tailed Student t
test or Mann-Whitney U test as appropriate. Cumulative sur-
vival was calculated by Kaplan-Meier methods with 95%
confidence limits. Statistical calculations were performed us-
ing the 17.0 SPSS (SPSS, Inc, Chicago, Ill) and Microsoft
Excel 2007 (Microsoft, Redmond,Wash) software packages.Perioperative stroke 0.7% (n ¼ 2)
Reoperation for>moderate AI 0.7% (n ¼ 2)
New onset pacemaker implantation 4% (n ¼ 12)
STS, Society Thoracic Surgeons; AVR, aortic valve replacement; AI, aortic
incompetence.RESULTS
A total of 299 patients received TA-AVI during the study
period. The mean age was 82.1 6.4 years and 209 patientsThe Journal of Thoracic and Ca(70%) were female. Additive EuroSCORE predicted risk of
mortality was 11.8 2.2, logistic EuroSCORE was 31%
16%, and Society of Thoracic Surgeons (STS) score was
12%  8%. Preoperative New York Heart Association
functional status was II in 49 (16.4%), III in 199
(66.6%), and IV in 51 (17%) patients. Data on preoperative
patient characteristics are supplied in Table 1. Perioperative
and follow-up outcome data are displayed in Table 2.
Stroke occurred in 2 patients during the in-hospital stay.
Both were extubated initially without any symptoms or
lateralizing neurologic signs, but then sudden incomplete
hemiparesis developed on postoperative day 1. Functional
recovery was good in both patients. During the overall
follow-up period, another 3 patients had a stroke. Tempo-
rary renal replacement therapy (continuous venovenous
hemodialysis or dialysis) was required in 15% of patientsrdiovascular Surgery c Volume 143, Number 2 327
TABLE 3. Patient outcomes in relation to the logistic EuroSCORE
Logistic EuroSCORE <20% 20%-40% >40%
N 80 142 77
Mean logistic EuroSCORE 15% 29% 53%
Mean STS score 9% 12% 17%
Thirty-day mortality 5% 9.8% 10.4%
Follow-up mortality 22% 25% 39%
STS, Society Thoracic Surgeons.
TABLE 4. Causes of death
Thirty-day
in-hospital Follow-up
Cardiac—circulatory
(LCOS, infarction, SCD,.)
53% 35%
Respiratory (failure, pneumonia,
pulmonary embolism,.)
23% 21%
MSOF, sepsis 12% 19%
Abdominalþcancer 8% 4%
Stroke, cerebral bleeding — 3%
Other (unclear, embolism, vasculitis,.) 4% 18%
LCOS, Low cardiac output syndrome; SCD, sudden cardiac death; MSOF, multisys-
tem organ failure.
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creatinine concentration of 2.1 mg/dL in comparison with
1.1 mg/dL for all other patients (P<.001).
Cardiopulmonary bypass (CPB) was used by intention in
10 patients at the beginning of the study. Thereafter, only
femoral guidewires were placed in patients as a ‘‘safety
net.’’ A total of 18 (6.3%) of 289 patients had to be con-
verted to CPB owing to hemodynamic instability, coronary
ischemia, annular tear, valve dysfunction requiring valve-
in-valve implantation, apical bleeding, or conversion to
conventional AVR surgery. The logistic EuroSCORE
(34%) and STS score (16.7%) were higher in patients
who required CPB conversion than in the remaining pa-
tients, and the 30-day mortality was significantly elevated
(44% compared with 6.6%, P ¼ .01).
More specifically, the following complications occurred:
A. Coronary ischemia in 9 (3%) patients owing to coro-
nary occlusion (n ¼ 1), impingement (n ¼ 7), or throm-
bosis (n ¼ 1)
B. Requirement for the implantation of a second SAPIEN
valve in 15 (5%) patients owing to low positioning
(n ¼ 7), leaflet dysfunction (n ¼ 5), ventricular septal
defect (n¼ 2), or upside down valve positioning (n¼ 1)
C. Annulus perforation in 3 (1%) patients
CPB had to be used in 66% (A), 20% (B), and 100% (C)
of these patients, and corresponding 30-day mortality was
44% (A), 27% (B), and 33% (C).
A total of 32 (10.7%) patients had 1 or more periopera-
tive complications, whereas 267 (89.3%) patients had anFIGURE 1. Overall survival. STS, Society of Thoracic Surgeons.
328 The Journal of Thoracic and Cardiovascular Surguneventful valve implantation. Logistic EuroSCORE was
35% versus 31%, STS score 14% versus 11.7%, and 30-
day mortality was 31% versus 6% in these 2 groups,
respectively.
Patient survival in relation to different logistic Euro-
SCORE subcategories (<20%, 20%-40%, and>40%) is
displayed in Table 3. Overall survival is displayed in
Figure 1. Thirty-day mortality for the entire group was
8.7%. However, 30-day mortality (17/150, 11.3%) was
lower for the first half of the patients (log EuroSCORE,
29.3%; STS score, 13.5%) than it was for the second half
of the patients (9/149, 6%) (log EuroSCORE, 33.3%;
STS score, 11.3%; P ¼ .053). There was no significant
change in patient risk profile during the study period.
Total mortality during the follow-up interval of 487 days
(range, 3 months to 4 years) was 28%. Causes of death are
displayed in Table 4.
Echocardiographic results are supplied in Table 5. No pa-
tient had structural valve degeneration during the current
follow-up period.
Mitral valve incompetence was absent in 7%, mild in
61%, moderate in 30%, and severe in 2% of patients pre-
operatively. During postoperative echocardiographic exam-
ination, there was an overall improvement in mitral
incompetence (absent in 23%, mild in 56%, moderate in
21%, and severe in none). Mortality at 30 days was 6%
for patients with no or mild preoperative mitral incompe-
tence and 20% for those with moderate or severe mitralTABLE 5. Echocardiographic results
n
Discharge
(256)
One year
(80)
Two years
(43)
Three years
(19)
Vmax (m/s) 1.9 2 1.9 2.1
Pmax (mm Hg) 12 11 12 13
Pmean (mm Hg) 8 5 5 6
EF (%) 56 58 58 59
AI
Mild (first degree) 37% 54% 53% 47%
Moderate 4% 4% 5% 5%
Vmax, Maximum transvalvular blood flow velocity; Pmax, maximum transvalvular
pressure gradient; EF, ejection fraction; AI, aortic incompetence.
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erative outcome was also assessed. Preoperative FEV1 and
vital capacity were 98% and 84% of normal in patients
who survived the procedure versus 85% and 68% in those
who died within 30 days (P<.01). Patients who died during
follow-up had a preoperative FEV1 and vital capacity of
80% and 71%, respectively.
DISCUSSION
TA-AVI and TF-AVI have been established as a clinically
accepted minimally invasive therapeutic option for high-
risk patients with AS in several centers across Europe. Cur-
rent literature results indicate a 30-day mortality rate in the
range of 10% for patients with higher risk profiles (ie, logis-
tic EuroSCORE values between 20% and 30%). In the ab-
sence of a randomized clinical trial comparing the TF and
TA approaches, it is currently unknown which procedure
offers a better alternative for patients. Despite this fact,
a ‘‘TF-first’’ strategy, whereby a TF approach is the default
procedure and TA-AVI is only offered in the presence of se-
vere peripheral vascular disease, has become the clinical
norm at most sites. We herein report our results of 299 con-
secutive high-risk patients with AS receiving TA-AVI by an
interdisciplinary team in a hybrid operative theater over 4
years. During this time period, a similar number of patients
underwent TF-AVI by the same team. Indications for TA-
AVI, although mostly based on patient referral patterns,
were in part directed by anatomic reasons. Of note, periph-
eral vascular disease was present in 47% of our TA-AVI pa-
tients, a proportion that is quite comparable with other
series in the literature. Our overall results were quite posi-
tive, particularly inasmuch as the current series includes
the early learning experience with TA-AVI. High-risk pa-
tients with AS, presenting with a mean logistic EuroSCORE
of 31% and an STS score of 12%, successfully underwent
minimally invasive treatment usually without CPB support.
Our observed 30-day mortality rate was acceptable in view
of the high-risk profile of our patients. Several series in the
literature have reported similar mortality rates in lower-risk
patients. When estimating risk for patients undergoing aor-
tic valve surgery, the STS score should always be consid-
ered foremost inasmuch as the logistic EuroSCORE is
known to lead to an overestimation of the effective
risk.13,14 Alternatively, the logistic EuroSCORE can be di-
vided by 3, which would lead to a mean predicted risk of
mortality of 10.5% in the current series, to get a more real-
istic estimate on a patient’s individual risk. Our observed
stroke risk was much lower than those reported for TF-
AVI, most likely owing to minimal manipulations of the
aortic arch when using the antegrade TA approach. Simi-
larly, several reports on T-AVI in the literature have dis-
played a very low or absent stroke rate, all of which were
performed using an antegrade TA approach.8,9,11,15 Patient
inclusion criteria were consistently applied throughout theThe Journal of Thoracic and Cacurrent study and only patients at high risk for conventional
AVRwere included, in agreement with recent recommenda-
tions.4 This is owing to the fact that conventional AVR
yields excellent results in regular risk patients of almost
any age,1-3 as well as our observations that unexpected, sud-
den, and occasionally life-threatening complications can
occur during all T-AVI procedures. Such complications
have led us to develop specific therapeutic approaches, as
described previously.12 These prophylactic and therapeutic
measures include temporary hemodynamic support using
inotropes to avoid hypotension in patients with hypertro-
phic ventricles, the placement of femoral guidewires to be
able to gain CPB access easily and rapidly in case of severe
hemodynaymic compromise, percutaneous coronary inter-
vention to treat coronary artery impingement, as well as
valve-in-valve implantation in the case of malposition
and/or malfunction of the initial prosthesis. As indicated
in Table 2, such complications occurred in a minority of pa-
tients. However, they occurred throughout the entire study
period and were not completely avoidable or foreseeable.
We can conclude from our experience that the surgical
team should be prepared for such complications to occur
at any time and to have a well thought out backup plan to
deal with such complications. Annular perforation was
a particularly troublesome complication that occurred in 3
(1%) patients. On the basis of this limited experience, iden-
tification of specific risk factors for this complication may
be difficult. Excessive calcification of the aortic valve cusps
and the aortic annulus together with mitral annular calcifi-
cation leading to reduced elasticity of the aortic root may
have been a contributing factor. We suggest that moderate
oversizing of 1 to 2 mm should be applied in such cases
and that aggressive oversizing be avoided. Treatment of
an annular perforation can be successfully performed with
conventional AVR surgery and patch closure of the defect.
In contrast, occurrence of a small ventricular septal defect,
most certainly owing to calcium penetrating the membra-
nous septum, can be successfully treated by valve-in- valve
implantation (ie, a second SAPIEN prosthesis inside the
first one). The team approach in a hybrid operative theater
allowed us to standardize the procedure leading to short op-
erative times of approximately 1 hour, as well as a relatively
low amount of administered contrast dye. Availability of
CPB, however, will remain a cornerstone of T-AVI therapy
in all patients for the foreseeable future. Respiratory dys-
function was strongly associated with decreased survival
in the current series. As such, respiratory dysfunction may
not be weighed sufficiently with current EuroSCORE risk
assessment. Our clinical experience with TF-AVI, however,
has also been somewhat disappointing in these challenging
patients. Causes of death as shown in Table 4 were mostly
cardiac, respiratory, and abdominal, as expected for an el-
derly high-risk population. Unknown causes of death
were also present in several patients during follow-up,rdiovascular Surgery c Volume 143, Number 2 329
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the low autopsy rate in elderly patients. When evaluating
the overall survival of our patient group, one must consider
that the mean patient age was 82 years at the time of valve
implantation. Although natural attrition will play a signifi-
cant role when evaluating postprocedure survival in T-AVI
patients, we believe that 1-year survival should be used as
an important clinical end point.
Risk subgroup analysis revealed that the logistic Euro-
SCORE as well as the STS score were able to predict patient
outcome relatively well, as shown in Table 3. Patients with
a lower risk score had improved perioperative and follow-
up survival. One may conclude from this observation that
lower-risk patients with AS should be treated with TA-
AVI. It must be kept in mind, however, that conventional
AVR is associated with very low operative risk and excel-
lent long-term outcomes in such patients. Furthermore,
the high costs of transcatheter valves may not be justified
in lower-risk patients. As mentioned previously, we have
learned that complications can occur any time during TA-
AVI and can usually be handled with a predefined therapeu-
tic strategy. Nevertheless, mortality is significantly higher
in patients who had a procedural complication. Therefore,
utmost attention should be given to precise valve size selec-
tion, implantation procedural access, and valve positioning
to obtain an optimal outcome. Despite potential procedural
complications, we observed an improvement in outcomes
over time. For the second half of patients in the current
study, 30-day mortality was reduced to 6% in a patient pop-
ulation with a similar risk score to the first half. We believe
this improvement is due to a learning effect, combined with
the fact that we were able to perform these procedures with-
out interruptions, as has occurred in other studies.16 Hemo-
dynamic function of the SAPIEN valve was excellent, as
indicated by low blood flow velocities and low pressure gra-
dients during echocardiographic examination (Table 5).
Left ventricular ejection fraction was well preserved during
follow-up.We can therefore conclude that the apical access,
as expected, does not lead to any ventricular compromise.
The excellent hemodynamic performance for such trans-
catheter valves, however, is tempered by the increased
risk of paravalvular leakage. A paravalvular leak was pres-
ent in more than 40% of patients in the current study. For-
tunately, paravalvular incompetence was mild in the vast
majority of our patients, and only 2 patients required reop-
eration for increasing aortic incompetence 6 weeks after the
procedure. In addition, clinically relevant hemolysis was
not observed in any patient. This observation may have
been due to the fact that the SAPIEN valve does not have
a sewing ring, thereby avoiding cellular trauma that occurs
when a regurgitant jet comes into contact with a rigid sew-
ing ring. Treatment of younger and more physically active
patients in the future, however, will require devices that
are able to achieve a better seal with the annulus and thus330 The Journal of Thoracic and Cardiovascular Surgavoid paravalvular leakage. Optimal imaging is the key
for successful T-AVI. Valve positioning should be
performed exactly intra-annular, but subcoronary. Valve im-
plantation is best performed under high-quality fluoro-
scopic and transesophageal echocardiographic control. We
recommend positioning of the SAPIEN valve with approx-
imately 40% of the stent above and 60% below the native
annulus, although Edwards recommends a 50/50 distribu-
tion. It must be kept in mind, however, that the aortic annu-
lus is scalloped and not planar and that the potential motion
and future position of the native calcified leaflets during
valve implantation are difficult to predict before deploy-
ment. Our recommendation on the height of implantation
is based on the need to avoid any coronary artery compro-
mise. Advanced imaging modalities such as perioperative
3-dimensional reconstruction with online overlay visualiza-
tion using the DynaCT technique (Siemens Inc, Forchheim,
Germany) may lead to better imaging quality and thus an
improved safety margin for the patients.17
The current study has several limitations, most impor-
tantly the relatively short follow-up period. More detailed
analysis of potential risk factors will have to be performed
from larger multicenter series to better identify ideal criteria
for T-AVI therapy. Further technological improvements, by
means of enhanced imaging as well as improved valve pros-
theses and delivery catheters, will also need to be investi-
gated to determine whether further improvements can be
achieved.
In summary, TA-AVI has evolved as an imminently
feasible minimally invasive therapeutic option for high-
risk patients with AS. Our experiences with the initial 299
patients over a 4-year period have led to an improvement
in outcomes over time. However, sudden and unpredictable
complications can occur at any time during T-AVI therapy.
We therefore recommend that such procedures be performed
in a hybrid operative theater by an experienced team of anes-
thetists, cardiologists, perfusionists, and cardiac surgeons.
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